Universal Registration Document

Overview

The report states that 2020 income came solely from named-patient Temporary Authorizations for Use for LUMEVOQ®. It highlights the September 2020 submission of LUMEVOQ® to the EMA for marketing authorization and continued Phase I/II development of GS030. The company reported 25 employees at year-end, with CSR disclosures covering employment, diversity, health and safety, training and environmental practices.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2020
Period: Ends 31 December 2020
Publication date: 8 April 2021
Language: English
Pages
File size
Restatement: Disclosed

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services